TMBIM4 and early-onset autosomal dominant Alzheimer disease: Preclinical studies in several animal models suggest that S1R agonists are promising drugs for the treatment of cognitive dysfunction [44], suggesting a new, and hopeful, pathway in development of novel therapies for neurodegenerative diseases as Alzheimer’s disease.